Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Insulin lispro may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Admelog is used to treat diabetes. It works more quickly than normal human insulin because the insulin molecule has been changed slightly. You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood. Admelog is a substitute for your own insulin and is used to control glucose in the long term. It works very quickly and lasts a shorter time than soluble insulin (2 to 5 hours). You should normally use Admelog within 15 minutes of a meal. Your doctor may tell you to use Admelog as well as a longer-acting insulin. Each kind of insulin comes with another patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin. Admelog is suitable for use in adults and children. Admelog SoloStar is a disposable pre-filled pen containing 3 ml (300 units, 100 units/ml) of insulin lispro. One Admelog pre-filled pen contains multiple doses of insulin. The Admelog pre-filled pen dials 1 unit at a time. The number of units are displayed in the dose window, always check this before your injection. You can give from 1 to 80 units in a single injection. If your dose is more than 80 units, you will need to give yourself more than one injection.
e Admelog Do not use Admelog
Skin changes at the injection site The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see "How to use Admelog"). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Talk to your doctor, pharmacist or nurse before using Admelog:
You should contact your doctor about the advisability of driving if you have:
Admelog Always check the pack and the label of the pre-filled pen for the name and type of the insulin when you get it from your pharmacy. Make sure you get the Admelog that your doctor has told you to use. Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. To prevent the possible transmission of disease, each pen must be used by you only, even if the needle is changed. Dose
If you use more Admelog than you should If you use more Admelog than you need or are unsure how much you have injected, a low blood sugar may occur. Check your blood sugar. If your blood sugar is low (mild hypoglycaemia), eat glucose tablets, sugar or drink a sugary drink. Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest. This will often get you over mild hypoglycaemia or a minor insulin overdose. If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once. A glucagon injection can treat quite severe hypoglycaemia. Eat glucose or sugar after the glucagon injection. If you do not respond to glucagon, you will have to go to hospital. Ask your doctor to tell you about glucagon. If you forget to use Admelog If you use less Admelog than you need or are unsure how much you have injected, a high blood sugar may occur. Check your blood sugar. If hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) is not treated, they can be very serious and cause headaches, feeling sick (nausea), being sick (vomiting), loss of fluids (dehydration), unconsciousness, coma or even death (see "Hypoglycaemia" and "Hyperglycaemia and diabetic ketoacidosis" in section 4 "Possible Side Effects"). Three simple steps to avoid hypoglycaemia or hyperglycaemia are:
Like all medicines, this medicine can cause side effects, although not everybody gets them. Systemic allergy is rare (may affect up to 1 in 1,000 people). The symptoms are as follows:
Common problems of diabetes A. Hypoglycaemia Hypoglycaemia (low blood sugar) means there is not enough sugar in the blood. This can be caused if:
Admelog Keep out of the sight and reach of children. Do not use Admelog in pre-filled pen after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month. Before the first use store your pre-filled pen in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect from light. Keep your Admelog pre-filled pen in use at room temperature (below 30 °C) and dispose of after 4 weeks. Do not keep the pre-filled pen that you are using in the fridge. The pre-filled pen should not be stored with the needle attached. Always keep the cap on the pre-filled pen when you are not using it in order to protect from light. Do not use Admelog pre-filled pen if the solution is coloured or it has solid pieces in it. You must use it only if it looks like water. Check this each time you inject yourself. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Admelog contains
Admelog solution for injection in pre-filled pen (SoloStar) INSTRUCTIONS FOR USE Need help?
Important information
this first
Never share your pen – it is only for you. Never use your pen if it is damaged or if you are not sure that it is working properly. Always perform a safety test. Always carry a spare pen and spare needles in case they got lost or stop working. Never re-use needles. If you do you might not get your dose (underdosing) or get too much (overdosing) as the needle could block.
Talk with your doctor, pharmacist or nurse about how to inject, before using your pen. Ask for help if you have problems handling the pen, for example if you have problems with your sight. This pen is not recommended for use by the blind or visually impaired without the help of someone trained to use the pen. Read all of these instructions before using your pen. If you do not follow all of these instructions, you may get too much or too little insulin.
If you have any questions about your pen or about diabetes, ask your doctor, pharmacist or nurse or call the Sanofi number on the front of this leaflet.
a new sterile needle (see STEP 2). a puncture resistant container for used needles and pens (see Throwing your pen away).
holder
window
pointer
selector Pen cap
Rubber seal
scale
Plunger*
Injection button
How to care for your pen Handle your pen with care
Take a new pen out of the fridge at least 1 hour before you inject. Cold insulin is more painful to inject.
Protect your pen from dust and dirt
Always use a new sterile needle for each injection. This helps stop blocked needles, contamination and infection. Only use needles that are compatible for use with Admelog.
Always do a safety test before each injection – this is to: check your pen and the needle are working properly. make sure that you get the correct insulin dose.
Remove the needle before throwing your pen away. Throw away your used pen as told by your pharmacist or local authority.
Never select a dose or press the injection button without a needle attached. This may damage your pen.
If you find it hard to press the injection button in, do not force it as this may break your pen. See the section below for help.
dose pointer is at the 2 mark.
pen. Make sure you have the correct insulin. This is especially important if you have other injector pens. Never use your pen after the expiry date.
Upper arms Stomach
until fixed. Do not overtighten.
When insulin comes out of the needle tip, your pen is working correctly.
Do not use the pen if the insulin looks cloudy, coloured or contains particles.
with your dose. If you turn past your dose, you can turn back down. If there are not enough units left in your pen for your dose, the dose selector will stop at the number of units left. If you cannot select your full prescribed dose, use a new pen or inject the remaining units and use a new pen to complete your dose.
Even numbers are shown in line with the dose pointer:
Buttocks
Thighs
pharmacist or nurse. Do not touch the injection button yet.
Take care when handling needles – this is to prevent needle injury and cross-infection. Never put the inner needle cap back on.
to unscrew the needle from the pen. To reduce the risk of accidental needle injury, never replace the inner needle cap. If your injection is given by another person, or if you are giving an injection to another person, special caution must be taken by this person when removing and disposing of the needle. Follow recommended safety measures for removal and disposal of needles (contact your doctor, pharmacist or nurse) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
container, or as told by your pharmacist or local authority.
in and hold. Do not press at an angle – your thumb could block the dose selector from turning. Do not put the pen back in the fridge.
You may need to repeat this step up to 3 times before seeing insulin. If no insulin comes out after the third time, the needle may be blocked. If this happens: change the needle (see STEP 6 and STEP 2), then repeat the safety test (STEP 3). Do not use your pen if there is still no insulin coming out of the needle tip. Use a new pen. Never use a syringe to remove insulin from your pen.
Odd numbers are shown as a line between even numbers:
dose window, slowly count to 10. This will make sure you get your full dose.
10 secs
button. Then remove the needle from your skin.
Take care when handling needles – this is to prevent needle injury and cross-infection.
You may see air bubbles in the insulin. This is normal, they will not harm you.
Your pen contains a total of 300 units of insulin. You can select doses from 1 to 80 units in steps of 1 unit. Each pen contains more than one dose. You can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale.
Change the needle (see STEP 6 and STEP 2) then do a safety test (see STEP 3). If you still find it hard to press in, get a new pen. Never use a syringe to remove insulin from your pen.
Admelog 100 units/ml solution for injection in pre filled pen comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Admelog 100 units/ml solution for injection in pre filled pen is insulin lispro.
Medicines with the same active substance, strength and form include: Admelog 100 units/ml solution for injection in cartridge, Admelog 100 units/ml solution for injection in vial, Humalog 100 units/ml Junior KwikPen, solution for injection in a pre-filled pen. In total there are 10 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Admelog 100 units/ml solution for injection in pre filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Admelog is also indicated for the initial stabilisation of diabetes mellitus.
Posology
The dose should be determined by the physician, according to the requirement of the patient.
Insulin lispro may be given shortly before meals. When necessary insulin lispro can be given soon after meals.
Insulin lispro takes effect rapidly and has a shorter duration of activity (2 – 5 hours) given subcutaneously as compared with regular insulin. This rapid onset of activity allows an Admelog injection (or, in the case of administration by continuous subcutaneous infusion, an Admelog bolus) to be given very close to mealtime. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. The faster onset of action compared to soluble human insulin is maintained regardless of injection site. As with all insulin preparations, the duration of action of insulin lispro is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Admelog can be used in conjunction with a longer-acting insulin or oral sulphonylurea medicinal products, on the advice of a physician.
Special populations
Renal impairment
Insulin requirements may be reduced in the presence of renal impairment.
Hepatic impairment
Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.
Paediatric population
Admelog can be used in adolescents and children (see section 5.1).
Method of administration
Admelog solution for injection should be given by subcutaneous injection or by continuous subcutaneous infusion pump (see section 4.2) and may, although not recommended, also be given by intramuscular injection.
If necessary, Admelog may also be administered intravenously, for example, for the control of blood glucose levels during ketoacidosis, acute illnesses or during intra and post-operative periods.
Subcutaneous administration of Admelog
Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).
When administered subcutaneously care should be taken when injecting Admelog to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the proper injection techniques.
Insulin lispro in pre-filled pen is available in two strengths (100 units/ml and 200 units/ml). However, Admelog in pre-filled pen is available in one strength only: 100 units/ml. For both, the needed dose is dialled in units. The number of insulin units is shown in the dose window of the pen regardless of strength and no dose conversion should be done when transferring a patient to a new strength or to another insulin lispro pre-filled pen with a different dose step.
Admelog in pre-filled pen delivers 1 – 80 units in increments of 1 unit in a single injection. Considering that Admelog is only available as 100 units/ml pre-filled pen, if an alternate strength is required, other insulin lispro medicinal products offering such an option should be used.
Admelog 100 units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used (see section 4.4).
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Hypoglycaemia.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Transferring a patient to another type or brand of insulin
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, etc.), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage. For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control.
Injection technique
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.
Hypoglycaemia or hyperglycaemia
Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease or medications such as beta-blockers.
A few patients who have experienced hypoglycaemic reactions after transfer from animal-source insulin to human insulin have reported that the early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin. Uncorrected hypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death.
The use of doses which are inadequate or discontinuation of treatment, especially in insulin-dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.
Insulin requirements and dosage adjustment
Insulin requirements may be increased during illness or emotional disturbances.
Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia. A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.
Combination of Admelog with pioglitazone
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind, if treatment with the combination of pioglitazone and Admelog is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs.
Avoidance of medication errors when using Admelog
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Admelog and other insulin products.
Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.
Admelog 100 units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used. To prevent the possible transmission of disease, each pen must be used by one patient only, even if the needle is changed.
Excipients
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.
Insulin requirements may be increased by medicinal products with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as ritodrine, salbutamol, terbutaline).
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
The physician should be consulted when using other medicinal products in addition to Admelog (see section 4.4).
Pregnancy
Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the fetus/newborn.
It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should be advised to inform their doctor if they are pregnant or are contemplating pregnancy. Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes.
Breast-feeding
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both.
Fertility
Insulin lispro did not induce fertility impairment in animal studies (see section 5.3).
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.
Summary of the safety profile
Hypoglycaemia is the most frequent adverse reaction of insulin therapy that a patient with diabetes may suffer. Severe hypoglycaemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors e.g. a patient`s level of diet and exercise.
Tabulated list of adverse reactions
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000) and not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
MedDRA system organ classes
Common
Uncommon
Rare
Not known
Immune system disorders
Local allergy
X
Systemic allergy
X
Skin and subcutaneous tissue disorders
Lipodystrophy
X
Cutaneous amyloidosis
X
Description of selected adverse reactions
Local allergy
Local allergy in patients is common. Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.
Systemic allergy
Systemic allergy, which is rare but potentially more serious, is a generalised allergy to insulin. It may cause a rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalised allergy may be life-threatening.
Skin and subcutaneous tissue disorders
Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
Oedema
Cases of oedema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Insulins have no specific overdose definitions because serum glucose concentrations are a result of complex interactions between insulin levels, glucose availability and other metabolic processes. Hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake and energy expenditure.
Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.
Mild hypoglycaemic episodes will respond to oral administration of glucose or other sugar or saccharated products.
Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fail to respond to glucagon must be given glucose solution intravenously.
If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously. However, glucose solution must be given intravenously if glucagon is not available or if the patient fails to respond to glucagon. The patient should be given a meal as soon as consciousness is recovered.
Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Ask anything about Admelog 100 units/ml solution for injection in pre filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.